Antiviral therapy for influenza : a clinical and economic comparative review

Drugs
Alexander C Schmidt

Abstract

Each year influenza epidemics cause a considerable burden of disease. Vaccination against influenza A and B viruses has been and remains the cornerstone of influenza prevention, but antiviral therapy can serve as an important adjunct to vaccination in controlling the impact of the disease. Two classes of drugs are currently licensed in a large number of countries for the treatment of influenza. The M2 ion channel blockers or amantadanes (amantadine and rimantadine) are specific inhibitors of influenza A virus replication, whereas the neuraminidase inhibitors (zanamivir and oseltamivir) are active against influenza A and B viruses. Readily transmissible drug-resistant viruses develop frequently during amantadane treatment but not during neuraminidase inhibitor treatment. In this review, efficacy and safety data from randomised controlled trials are evaluated to gain an understanding of what we can and cannot expect from antiviral treatment. All four drugs shorten the course of influenza disease by approximately 1 day and relieve symptoms to some extent, but there is still uncertainty as to whether antiviral therapy leads to a reduction of serious complications and hospitalisation. The results of cost-effectiveness analyses are v...Continue Reading

References

Mar 11, 2000·Lancet·L V GubarevaF G Hayden
Aug 21, 2002·Annals of Internal Medicine·Patrick Y LeeEric D Peterson

❮ Previous
Next ❯

Citations

Mar 29, 2006·Intensive Care Medicine·Pascale C GruberGavin M Joynt
Feb 7, 2013·Best Practice & Research. Clinical Gastroenterology·Bincy P Abraham, Joseph H Sellin
May 26, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Torsten ArndtJanine Reis
Sep 29, 2011·Journal of the American Chemical Society·Jiun-Jie ShieChi-Huey Wong
Sep 27, 2012·Journal of Medicinal Chemistry·Ting-Jen R ChengChi-Huey Wong
Jun 8, 2011·Immunology and Cell Biology·Garry W LynchJohn S Sullivan
Jul 27, 2007·Chemical Communications : Chem Comm·Karen M BromfieldNina Kann
Apr 13, 2006·Clinical Nurse Specialist CNS·Patricia O'Malley
Apr 7, 2007·Critical Care Medicine·Yaseen ArabiZiad A Memish
Nov 3, 2007·Current Opinion in Critical Care·Charles D GomersallBruce L Taylor
Oct 15, 2008·PharmacoEconomics·Martin Keech, Paul Beardsworth
Mar 22, 2014·Journal of Medicinal Chemistry·Caitlin A MooneyNathaniel I Martin
Oct 11, 2013·Organic & Biomolecular Chemistry·Chih-An Chen, Jim-Min Fang
Jun 30, 2009·Dalton Transactions : an International Journal of Inorganic Chemistry·Karen M BromfieldNina Kann
Oct 5, 2013·The Journal of Organic Chemistry·Pal John Pal AdabalaB Mario Pinto
Jan 1, 2008·Journal of Medical Economics·Maarten J PostmaJan C Wilschut
Oct 6, 2007·Expert Opinion on Drug Metabolism & Toxicology·Richard J Whitley
Feb 22, 2012·Bioorganic & Medicinal Chemistry Letters·Jiangyu Zhao, Haji Akber Aisa
Dec 9, 2009·Advances in Pediatrics·Kam-Lun Hon, Alexander K C Leung
Apr 15, 2008·Emergency Medicine Clinics of North America·Daniel R MartinJoseph F Plouffe
Sep 9, 2005·Chembiochem : a European Journal of Chemical Biology·Laiqiang Ying, Jacquelyn Gervay-Hague
Dec 13, 2006·Medicinal Research Reviews·Irene M Lagoja, Erik De Clercq
Apr 25, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Monika LindemannHans Grosse-Wilde
Oct 4, 2005·Lancet·Yi Guan, Honglin Chen
May 20, 2014·European Journal of Medicinal Chemistry·Chun-Lin ChenChi-Huey Wong
Aug 4, 2016·European Journal of Medicinal Chemistry·Anindya DasChun-Cheng Lin
Nov 19, 2009·The Annals of Pharmacotherapy·Donna SymGladys M El-Chaar
Aug 3, 2011·Der Internist·G G U Rohde
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Márcia G Alves GalvãoAntonio J L Alves da Cunha
Oct 24, 2019·Journal of Biomedical Science·Jiun-Jie Shie, Jim-Min Fang
Mar 9, 2019·Science·Maria J P van DongenIan A Wilson
Jan 8, 2021·Biotechnology Journal·Jingdi Pan, Zongqiang Cui
Feb 2, 2021·Nano Today·Jiarong ZhouLiangfang Zhang
Apr 17, 2010·The Journal of Organic Chemistry·Jiang WengGui Lu
Apr 16, 2009·The Journal of Organic Chemistry·Liang-Deng NieWei-Dong Lu
Jul 3, 2021·Viruses·Esen SokulluBenoit Coulombe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.